Drug delivery to the respiratory tract using dry powder inhalers

Timsina, M.P.; Martin, Gary P.; Marriott, Christopher; Ganderton, D.; Yianneskis, M.

doi:10.1016/0378-5173(94)90070-1

Cited by 281 publications

(85 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Dry powder inhalers are portable, easy to operate (breath-actuated), inexpensive, propellant-free, and show improved stability of the formulation as a result of the dry state. 7,8 The aim of our study was to optimize the systemic delivery of the 1-34 fragment of human parathyroid hormone using inhalation dry powders. We prepared powders with sugars and compounds endogenous to the lung such as albumin and dipalmitoylphosphatidylcholine (DPPC) by spray-drying, and analyzed their aerosolization properties as well as the chemical integrity of the peptide incorporated.…”

Section: Introductionmentioning

confidence: 99%

Systemic delivery of parathyroid hormone (1-34) using inhalation dry powders in rats

Codrons

Vanderbist

Verbeeck

et al. 2003

Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

The aim of this work was to prepare and characterize inhalation dry powders of human parathyroid hormone (PTH), as well as to assess their efficacy for systemic delivery of the peptide and safety in rats. The powders were prepared by spray-drying using PTH, sugars, dipalmitoylphosphatidylcholine, and/or albumin. They presented an average primary particle diameter of 4.5 mm and tap density of 0.06 g/cm 3 , a mass median aerodynamic diameter between 3.9 and 5.9 mm, and reached up to 98% emitted dose and up to 61% fine particle fraction in the multi-stage liquid impinger using a Spinhaler inhaler device. Varying the airflow rate from 30 to 100 L/min had limited influence on the aerodynamic behavior of the aerosols. The absolute PTH bioavailability was 21% after intratracheal administration of the powder formed of PTH/albumin/ lactose/dipalmitoylphosphatidylcholine and 18% after subcutaneous injection in rats. Equilibrium dialysis revealed a 78% binding of PTH to albumin and the withdrawal of albumin from the powder increased absolute bioavailability after inhalation from 21 to 34%. No acute inflammation appeared in the lung up to 48 h after a single inhalation. The increased bioavailability of the optimized powder aerosol of PTH makes it a promising alternative to subcutaneous injection. ß

show abstract

Section: Introductionmentioning

confidence: 99%

Systemic delivery of parathyroid hormone (1-34) using inhalation dry powders in rats

Codrons

Vanderbist

Verbeeck

et al. 2003

Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

show abstract

“…As a technique for delivering drugs to the lung, dry powder inhalation is considered one of the most promising [1][2][3][4][5][6] due to its many advantages, such as (1) absence of the need for propellants such as chlorofluorocarbon, (2) portability, and (3) relatively low cost. 7,8) For inhalation of a drug powder into the lungs and its deposition, efficiently dispersed drugs with an aerodynamic diameter of 1.0-6.0 mm are most effective for the delivery of particles. 9) Thus, dry powder inhalations have been formulated with micronized drug particles of about a few micrometers in size.…”

mentioning

confidence: 99%

Preparation of Dry Powder Inhalation by Surface Treatment of Lactose Carrier Particles.

et al. 2003

View full text Add to dashboard Cite

An attempt was made to produce carrier particles for dry powder inhalations by the surface treatment of lactose particles with aqueous ethanol solution. Drug/carrier powder mixtures were prepared consisting of lactose carriers with different particle surface properties and micronized salbutamol sulfate. These powder mixtures were aerosolized by Spinhaler ® , and in vitro deposition properties of salbutamol sulfate were evaluated by twin impinger. The degree of adhesion between drug particles and carrier particles was determined by the ultracentrifuge separation method. In addition, the air jet sieve method was used to evaluate characteristics of the separation of drug particles from carrier particles in airflow. The average adhesion force (F50) between the surface-treated lactose carrier and drug particles was significantly lower than that of powder mixed with the untreated lactose carrier, indicating that the degree of separation (T50) of drug particles from carrier particles was improved when surface-treated lactose carrier was used. This resulted in an improvement of in vitro inhalation properties.

show abstract

“…For both types of devices, suitable powder flow properties are essential, either for accurate dosing or emptying of the single-dose container entirely. Since flow properties of micronized powders are often poor, most formulations consist of physical blends of drug particles with larger (30-90 μm) carrier particles such as lactose, to aid deagglomeration and powder flow (35). In light of the aforementioned considerations, the ideal DPI would reproducibly deliver an accurate dose, regardless of a patient's condition.…”

Section: General Requirements For Dry Powder Inhalation Devicesmentioning

confidence: 99%

Devices for Dry Powder Drug Delivery to the Lung

2015

View full text Add to dashboard Cite

Abstract. Dry powder inhalers (DPIs) are an important and increasingly investigated method of modern therapy for a growing number of respiratory diseases. DPIs are a promising option for certain patient populations, and may help to overcome several limitations that are associated with other types of inhalation delivery systems (e.g., accuracy and reproducibility of the dose delivered, compliance and adherence issues, or environmental aspects). Today, more than 20 different dry powder inhalers are on the market to deliver active pharmaceutical ingredients (APIs) for local and/or systemic therapy. Depending on the mechanism of deagglomeration, aerosolization, dose metering accuracy, and the interpatient variability, dry powder inhalers demonstrate varying performance levels. During development, manufacturers focus on improving aspects characteristic of their specific DPI devices, depending on the intended type of application and any particular requirements associated with it. With the wide variety of applications related to specific APIs, there exists a range of different devices with distinct features. In addition to the routinely used multi-use DPIs, several single-use disposable devices are under development or already approved. The recent introduction of disposable devices will expand the range of possible applications for use by including agents such as vaccines, analgesics, or even rescue medications. This review article discusses the performance and advantages of recently approved dry powder inhalers as well as disposable single-use inhalers that are currently under development.

show abstract

Drug delivery to the respiratory tract using dry powder inhalers

Cited by 281 publications

References 37 publications

Systemic delivery of parathyroid hormone (1-34) using inhalation dry powders in rats

Systemic delivery of parathyroid hormone (1-34) using inhalation dry powders in rats

Preparation of Dry Powder Inhalation by Surface Treatment of Lactose Carrier Particles.

Devices for Dry Powder Drug Delivery to the Lung

Contact Info

Product

Resources

About